Review article · 2026 · Open access
Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors
Frontiers in Immunology, 17, 1774471 · Published 20 May 2026 · DOI 10.3389/fimmu.2026.1774471
In brief
“Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors” is a 2026 review article by Xinyi Wu and 4 co-authors, published in Frontiers in Immunology. OpenAlex counts 3 citations as of 18 November 2026, which puts it in the top 4% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 3
- Most cited in
- 2026 (3)
- Field-weighted impact
- 2.24
- References
- 130
- Authors
- 5
Abstract
T cell engagers (TCEs) are a class of T cell-redirecting therapeutics that enhance antitumor immunity by bringing T cells into close proximity with malignant cells. Following their success in hematologic malignancies, TCEs are now being increasingly investigated for the treatment of solid tumors. The recent approval of tarlatamab for small cell lung cancer (SCLC) offers renewed hope in this setting. Nevertheless, clinical efficacy in solid tumors remains limited by immunosuppressive tumor microenvironments (TME), on-target/off-tumor toxicity, and intrinsic or acquired resistance to TCEs. This review summarizes recent advances in TCE development for solid tumors, including refinements in molecular design, biomarker-guided patient selection, and rational combination strategies aimed at overcoming resistance and improving therapeutic outcomes. We also discuss emerging next-generation approaches, such as engager platforms that redirect other immune effector cells. Collectively, these innovations underscore the potential of more precise and effective engager-based therapies for solid tumors.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Wu, X., Li, P., Li, T., Fan, Q., & Wu, H. W. (2026). Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors. Frontiers in Immunology, 17, 1774471. https://doi.org/10.3389/fimmu.2026.1774471
MLA 9
Wu, Xinyi, et al. “Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors.” Frontiers in Immunology, vol. 17, 2026, p. 1774471. https://doi.org/10.3389/fimmu.2026.1774471.
Chicago
Wu, Xinyi, Ping Li, Tao Li, Qiwen Fan, and H W Wu. 2026. “Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors.” Frontiers in Immunology 17: 1774471. https://doi.org/10.3389/fimmu.2026.1774471.
Harvard
Wu, X. et al. (2026) ‘Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors’, Frontiers in Immunology, 17, p. 1774471. doi:10.3389/fimmu.2026.1774471.
IEEE
X. Wu, P. Li, T. Li, Q. Fan, and H. W. Wu, “Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors,” Frontiers in Immunology, vol. 17, p. 1774471, 2026, doi: 10.3389/fimmu.2026.1774471.
BibTeX
@article{wu2026revolutionizing,
title = {{Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors}},
author = {Wu, Xinyi and Li, Ping and Li, Tao and Fan, Qiwen and Wu, H W},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
pages = {1774471},
doi = {10.3389/fimmu.2026.1774471},
url = {https://doi.org/10.3389/fimmu.2026.1774471}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- T-cell engagers
- solid tumors
- small cell lung cancer
- tarlatamab
- immunosuppressive tumor microenvironment
- on-target off-tumor toxicity
- biomarker-guided patient selection
- combination therapy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Wu, X., Li, P., Li, T., Fan, Q., & Wu, H. W. (2026). Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors. Frontiers in Immunology, 17, 1774471. https://doi.org/10.3389/fimmu.2026.1774471
How many times has this paper been cited?
3 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Xinyi Wu, Ping Li, Tao Li, Qiwen Fan, H W Wu.
What is the DOI of this paper?
10.3389/fimmu.2026.1774471, permanently at https://doi.org/10.3389/fimmu.2026.1774471. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.